சுருக்கம்

Review on New Oral Anticoagulants

Anusha Badarla

Vitamin K antagonist is the sole classification of oral anticoagulants available to clinicians for a long time. Be that as it may, with the North American country Food and Drug Administration endorsement of late oral anticoagulants, as dabigatran, rivaroxaban, and apixaban, clinicians as of now have a more extensive option. Given the late endorsement and handiness of those drugs, numerous questions emerge though choosing that of them would be best fitted to a particular patient. This content gives an aphoristic survey to clinicians involving the most studies that assessed the solidity and wellbeing of those pharmaceutical, their pharmacokinetic and pharmacodynamic properties, and a sensible way to deal with their clinical use. For this review, we tend to led pursuits of PubMed and MEDLINE for articles printed between Jan one, 2000, and Jan thirty, 2013, exploitation the consequent pursuit terms: oral anticoagulants, dabigatran, apixaban, rivaroxaban, novel anticoagulants, and injury difficulties, administration of injury inconveniences, pharmacodynamics, and materia medica.